At 211 MAb 81C6

N/A

Report date: 2025/10/20 14:18:12

Base Information

Drug NameAt 211 MAb 81C6

Drug Alias NameAt 211 antitenascin monoclonal antibody 81C6monoclonal antibody (MAb) Astatine At 211 Antitenascin Human/Mouse Chimeric 81C6At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6At-211-MAb-81C6

ClassificationRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of Actionanti-Tenascin

TargetsTenascin

Therapy Area/IndicationsCNS Embryonal TumorNeoplasm MetastasisNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesDuke University National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDuke University National Cancer Institute

Active IndicationsN/A

Inactive IndicationsCNS Embryonal TumorNeoplasm MetastasisNeuroblastoma

Other Information

ATC CodeN/A